Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 06, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 --...
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 02, 2024 16:10 ET
|
Dyne Therapeutics, Inc.
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne...
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
May 02, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294...
Enovis Announces First Quarter 2024 Results
May 02, 2024 06:00 ET
|
Enovis Corporation
Strong start to the year with sales growth of 27% on a reported basis and strong adjusted margin expansionReported first-quarter net loss from continuing operations of $1.32 per share with adjusted...
Kamari Pharma Appoints Dr. John Doux to its Board of Directors
April 30, 2024 09:00 ET
|
Kamari Pharma
NESS ZIONA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- Kamari Pharma, a privately-held clinical stage biotechnology company developing first and best-in-class treatments for rare and severe genetic...
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
April 30, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson’s...
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
April 30, 2024 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
ASLAN management will present new data from the interim analysis of the TREK-DX studyRegister here to attend the webinar event on May 7, 2024 at 8:00 AM ET SAN MATEO, Calif. and SINGAPORE,...
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
April 25, 2024 10:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
April 25, 2024 01:30 ET
|
ONWARD Medical NV
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date
Verana Health Announces Launch of Qdata® Thyroid Eye Disease
April 24, 2024 09:00 ET
|
Verana Health, Inc.
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), today...